14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
EW vs SNN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
EW Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)
EW Overall Winner
6-Pillar Tally: EW 3 – 3 SNN
Matrix Metrics: EW 6 – 4 SNN
As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Smith & Nephew plc (SNN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas SNN carries 42.0/100 (HOLD) at $31.01 (13.2x Forward P/E, 14.2% operating margin).
Composite vs. Pillar Nuance: While SNN currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. EW 31.5/100 SELL), EW captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (28.8% vs. 14.2% operating margin) and revenue trajectory (+10.5% vs. +4.6% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EW vs SNN. Trailing 12-month operating profitability (EW 28.8% vs SNN 14.2%) and valuation multiples (EW 31.6x vs SNN 13.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $13.2B market capitalization and 14.2% operating margin.
OpEx & R&D Reinvestment54.2% of Rev ($3.41B)
90D Engineering Disclosures0 Published
Investor FAQ EW vs SNN Key Questions & Quantitative Answers
As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Smith & Nephew plc (SNN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas SNN carries 42.0/100 (HOLD) at $31.01 (13.2x Forward P/E, 14.2% operating margin). Composite vs. Pillar Nuance: While SNN currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. EW 31.5/100 SELL), EW captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (28.8% vs. 14.2% operating margin) and revenue trajectory (+10.5% vs. +4.6% YoY).
EW leads the Growth & Scale pillar: EW posts +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin), compared with SNN at +4.6% YoY revenue growth and +5.7% YoY earnings growth on $6.30B TTM revenue (68.4% gross margin, 14.2% operating margin). On trailing 12-month operating scale, EW generates $6.67B in USD-normalized revenue versus $6.30B for SNN. In operating R&D and SG&A reinvestment, EW deploys 49.2% of Rev ($3.28B) (0 90-day corporate R&D disclosures) versus 54.2% of Rev ($3.41B) (0 disclosures) for SNN.
SNN screens cheaper on headline valuation multiples. EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin), whereas SNN trades at 13.2x Forward P/E, 21.4x Trailing P/E, 1.07x PEG, and 2.1x EV/Revenue (21.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EW (9.3% ROE) versus SNN (11.8% ROE) capital efficiency.
In options market volatility and institutional positioning, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk). By comparison, SNN carries 19.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 38% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.